NVNO vs. ICCM, SEPA, NSPR, SRTS, HSAQ, AMIX, APYX, XAIR, DXR, and MGRM
Should you be buying enVVeno Medical stock or one of its competitors? The main competitors of enVVeno Medical include IceCure Medical (ICCM), SEP Acquisition (SEPA), InspireMD (NSPR), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Autonomix Medical (AMIX), Apyx Medical (APYX), Beyond Air (XAIR), Daxor (DXR), and Monogram Orthopaedics (MGRM). These companies are all part of the "surgical & medical instruments" industry.
IceCure Medical (NASDAQ:ICCM) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability.
IceCure Medical has higher revenue and earnings than enVVeno Medical. IceCure Medical is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.
enVVeno Medical has a net margin of 0.00% compared to enVVeno Medical's net margin of -453.76%. IceCure Medical's return on equity of -70.17% beat enVVeno Medical's return on equity.
IceCure Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
enVVeno Medical received 139 more outperform votes than IceCure Medical when rated by MarketBeat users. However, 94.44% of users gave IceCure Medical an outperform vote while only 62.65% of users gave enVVeno Medical an outperform vote.
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 17.0% of enVVeno Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
IceCure Medical presently has a consensus target price of $2.95, suggesting a potential upside of 141.80%. Given enVVeno Medical's higher possible upside, analysts clearly believe IceCure Medical is more favorable than enVVeno Medical.
In the previous week, enVVeno Medical had 1 more articles in the media than IceCure Medical. MarketBeat recorded 2 mentions for enVVeno Medical and 1 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.62 beat enVVeno Medical's score of 0.33 indicating that enVVeno Medical is being referred to more favorably in the news media.
Summary
enVVeno Medical beats IceCure Medical on 10 of the 16 factors compared between the two stocks.
Get enVVeno Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
enVVeno Medical Competitors List
Related Companies and Tools
